Shanghai Haohai Biological Technology Co., Ltd.
Shanghai Haohai Biological Technology Co., Ltd. Fundamental Analysis
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) shows weak financial fundamentals with a PE ratio of 16.45, profit margin of 10.24%, and ROE of 4.51%. The company generates $4.7B in annual revenue with weak year-over-year growth of 1.70%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 46.4/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 6826.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak6826.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent6826.HK trades at attractive valuation levels.
Growth Score
Weak6826.HK faces weak or negative growth trends.
Financial Health Score
Excellent6826.HK maintains a strong and stable balance sheet.
Profitability Score
Weak6826.HK struggles to sustain strong margins.
Key Financial Metrics
Is 6826.HK Expensive or Cheap?
P/E Ratio
6826.HK trades at 16.45 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 6826.HK's PEG of -0.60 indicates potential undervaluation.
Price to Book
The market values Shanghai Haohai Biological Technology Co., Ltd. at 0.76 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 33.97 times EBITDA. This signals the market has high growth expectations.
How Well Does 6826.HK Make Money?
Net Profit Margin
For every $100 in sales, Shanghai Haohai Biological Technology Co., Ltd. keeps $10.24 as profit after all expenses.
Operating Margin
Core operations generate 4.68 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $4.51 in profit for every $100 of shareholder equity.
ROA
Shanghai Haohai Biological Technology Co., Ltd. generates $3.74 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Shanghai Haohai Biological Technology Co., Ltd. generates strong operating cash flow of $1.23B, reflecting robust business health.
Free Cash Flow
Shanghai Haohai Biological Technology Co., Ltd. generates strong free cash flow of $865.94M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $2.15 in free cash annually.
FCF Yield
6826.HK converts 5.71% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
16.45
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.60
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.76
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.22
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.07
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.79
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.05
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
0.02
vs 25 benchmark
How 6826.HK Stacks Against Its Sector Peers
| Metric | 6826.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 16.45 | 28.31 | Better (Cheaper) |
| ROE | 4.51% | 699.00% | Weak |
| Net Margin | 10.24% | -130884.00% (disorted) | Strong |
| Debt/Equity | 0.07 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 3.79 | 2775.16 | Strong Liquidity |
| ROA | 3.74% | -14469.00% (disorted) | Weak |
6826.HK outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Shanghai Haohai Biological Technology Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
28.14%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-13.49%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
41.82%
Industry Style: Defensive, Growth, Innovation
High Growth